Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.

[1]  Ann Marie Schmidt,et al.  Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.

[2]  Y. Tomino,et al.  Glomerular changes in the KK‐Ay/Ta mouse: A possible model for human type 2 diabetic nephropathy , 2006, Nephrology.

[3]  M. Nangaku,et al.  Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. , 2005, Kidney international.

[4]  Yusuke Suzuki,et al.  Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  R. Bucala,et al.  AGEs activate mesangial TGF-b –Smad signaling via an angiotensin II type I receptor interaction , 2010 .

[6]  Y. Tomino,et al.  Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. , 2004, Metabolism: clinical and experimental.

[7]  S. Levine,et al.  Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein‐deficient diet , 2004, Journal of applied toxicology : JAT.

[8]  Sushil K. Jain,et al.  Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes. , 2004, Free radical biology & medicine.

[9]  E. Van Obberghen,et al.  Human Glycated Albumin Affects Glucose Metabolism in L6 Skeletal Muscle Cells by Impairing Insulin-induced Insulin Receptor Substrate (IRS) Signaling through a Protein Kinase Cα-mediated Mechanism* , 2003, Journal of Biological Chemistry.

[10]  T. Metz,et al.  Pyridoxamine Traps Intermediates in Lipid Peroxidation Reactions in Vivo , 2003, Journal of Biological Chemistry.

[11]  J. Baynes,et al.  The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.

[12]  S. Horiuchi,et al.  CD36‐mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3‐L1 and human subcutaneous adipocytes , 2003, FEBS letters.

[13]  S. Levine,et al.  Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[14]  S. Horiuchi,et al.  Peroxynitrite induces formation of N( epsilon )-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. , 2002, Diabetes.

[15]  E. Fisher,et al.  Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. , 2002, Diabetes.

[16]  Z. Makita,et al.  Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[17]  N. Ruderman,et al.  Hyperglycemia and Insulin Resistance: Possible Mechanisms , 2002, Annals of the New York Academy of Sciences.

[18]  R. Nagaraj,et al.  Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. , 2002, Archives of biochemistry and biophysics.

[19]  K. Oguchi,et al.  Diabetic nephropathy in KK and KK-Ay mice. , 2002, Experimental animals.

[20]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[21]  T. Metz,et al.  A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.

[22]  Maristela L Onozato,et al.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. , 2002, Kidney international.

[23]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[24]  S. Jain,et al.  Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. , 2001, Free radical biology & medicine.

[25]  A. Barden,et al.  Advanced Glycation End Products: A Review , 2013 .

[26]  K. Kannan,et al.  Oxidative stress and apoptosis. , 2000, Pathophysiology : the official journal of the International Society for Pathophysiology.

[27]  A. Jenkins,et al.  Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.

[28]  B. Jortner.  Mechanisms of Toxic Injury in the Peripheral Nervous System: Neuropathologic Considerations , 2000, Toxicologic pathology.

[29]  R. Khalifah,et al.  Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.

[30]  Z. Makita,et al.  Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.

[31]  D. B. Mccormick,et al.  Update on interconversions of vitamin B-6 with its coenzyme. , 1999, The Journal of nutrition.

[32]  Alan W. Stitt.  Advanced Glycation Endproducts , 1999 .

[33]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[34]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[35]  V. Monnier,et al.  Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. , 1997, The Journal of clinical investigation.

[36]  N. Hotta,et al.  Effects of Glycemic Control on Plasma 3-Deoxyglucosone Levels in NIDDM Patients , 1997, Diabetes Care.

[37]  S. I. Kim,et al.  Pathogenic role of advanced glycosylation end products in diabetic nephropathy. , 1997, Kidney international. Supplement.

[38]  Z. Makita,et al.  Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.

[39]  A. Booth,et al.  In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs) , 1997, The Journal of Biological Chemistry.

[40]  J. Wautier,et al.  Advanced glycation end products, oxidant stress and vascular lesions , 1997, European journal of clinical investigation.

[41]  J. Mott,et al.  Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. , 1996, Biochemistry.

[42]  F. Ziyadeh,et al.  Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. , 1996, Journal of the American Society of Nephrology : JASN.

[43]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[44]  M. Nishimura.  Breeding of mice strains for diabetes mellitus , 1969 .